Evidence map›Paper›PMID 31581637›Full record

ArticleJournal of personalized medicine2019

Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail.

Marija Bosilkovska, Gaelle Magliocco, Jules Desmeules, Caroline Samer, Youssef Daali

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Marija BosilkovskaDivision of Clinical Pharmacology and Toxicology, Geneva University Hospitals, 1205 Geneva, Switzerland. marija.bosilkovska@hcuge.ch.
Gaelle MaglioccoDivision of Clinical Pharmacology and Toxicology, Geneva University Hospitals, 1205 Geneva, Switzerland. gaelle.magliocco@unige.ch.ORCID 0000-0003-4352-5440
Jules DesmeulesDivision of Clinical Pharmacology and Toxicology, Geneva University Hospitals, 1205 Geneva, Switzerland. jules.desmeules@hcuge.ch.
Caroline SamerDivision of Clinical Pharmacology and Toxicology, Geneva University Hospitals, 1205 Geneva, Switzerland. caroline.samer@hcuge.ch.
Youssef DaaliDivision of Clinical Pharmacology and Toxicology, Geneva University Hospitals, 1205 Geneva, Switzerland. youssef.daali@hcuge.ch.ORCID 0000-0002-8391-9383
University of Geneva · CHUniversity Hospital of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug metabolic enzymes and transporters are responsible for an important variability in drug disposition. The cocktail approach is a sound strategy for the simultaneous evaluation of several enzyme and transporter activities for a personalized dosage of medications. Recently, we have demonstrated the reliability of the Geneva cocktail, combining the use of dried blood spots (DBS) and reduced dose of phenotyping drugs for the evaluation of the activity of six cytochromes and P-glycoprotein (P-gp). As part of a study evaluating potential drug-drug interactions between probe drugs of the Geneva cocktail, the present paper focuses on the impact of cytochromes (CYP) probe drugs on the disposition of fexofenadine, a P-gp test drug. In a randomized four-way Latin-square crossover study, 30 healthy volunteers (15 men and 15 women) received caffeine 50 mg, bupropion 20 mg, flurbiprofen 10 mg, omeprazole 10 mg, dextromethorphan 10 mg, midazolam 1 mg, and fexofenadine 25 mg alone (or as part of a previously validated combination) and all together (Geneva cocktail). The determination of drug concentrations was performed in DBS samples and pharmacokinetic parameters were calculated. Fexofenadine AUC

Indexed as

cocktailP-glycoproteinphenotypingprecision medicine

Identifiers

PMID31581637
PMCPMC6963818
OpenAlexW2979224332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.